Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fred Hutchinson Cancer Center
OBJECTIVES:
I. To determine whether the incidence of nausea and vomiting related to administration of autologous hematopoetic stem cells cryopreserved in DMSO can be reduced by the use of a single dose of intravenous ondansetron prior to the stem cell infusion.
II. To determine the number of patients who experience nausea and vomiting.
OUTLINE: Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Inclusion
Autologous PBSC transplant patient
English-speaking
Planned cryopreserved PBSC infusion at the SCCA outpatient clinic
Exclusion
History of prior autologous transplant
Non-English-speaking
Planned cryopreserved PBSC infusion at the UWMC inpatient unit
Infusion of cryopreserved PBSC that are thawed and washed to remove DMSO prior to infusion
Allergy or adverse reaction to ondansetron
Clareo Health | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
